ElucidVivo A.3 vs ClearRead CT

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

ElucidVivo A.3

by Elucid

ClearRead CT

by RIVERAIN TECHNOLOGIES

AI Verdict

ElucidVivo A.3 specializes in detailed quantitative analysis of arterial plaque composition and stability for atherosclerosis patient stratification, including features like LRNC quantification and FFRct derivation. ClearRead CT, while also offering coronary artery calcification scoring, primarily focuses on enhancing pulmonary nodule detection and overall radiology workflow efficiency. Therefore, ElucidVivo A.3 is better suited for in-depth cardiovascular plaque assessment, while ClearRead CT excels in broader cardiothoracic screening and nodule management.

Choose ElucidVivo A.3 if…

Choose ElucidVivo A.3 if your primary goal is a detailed, quantitative assessment of arterial plaque composition and stability to stratify atherosclerosis patients. This tool excels at visualizing and measuring specific plaque characteristics, such as Lipid-Rich Necrotic Core, from CT angiography, which is crucial for understanding disease progression and optimizing treatment decisions.

View ElucidVivo A.3 →

Choose ClearRead CT if…

Choose ClearRead CT if your focus is on improving the accuracy and efficiency of pulmonary nodule detection and tracking, alongside opportunistic coronary artery calcification scoring. Its AI-powered vessel suppression and automated nodule characterization features are ideal for streamlining radiology workflows and reducing missed actionable nodules in cardiothoracic CT scans.

View ClearRead CT →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	ElucidVivo A.3	ClearRead CT
Pricing	Unknown	Contact for pricing
Deployment	Cloud and on-premise secure deployment.	On-premise (stand-alone server, virtual machine) and Cloud
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

ClearRead CT

ClearRead CT explicitly highlights significant reductions in reading time (up to 36%) and seamless PACS integration, allowing radiologists to stay within their existing workflow without opening separate applications. This direct impact on efficiency and ease of use gives it a clear advantage in usability. While ElucidVivo A.3 offers detailed visualizations and follows typical clinical workflows, it does not provide the same quantifiable improvements in reading efficiency.

Clinical Value

ElucidVivo A.3

While both tools offer significant clinical value, ElucidVivo A.3 provides a more profound and predictive clinical insight by quantifying arterial plaque composition and stability, validated against histology, and deriving fractional flow reserve (FFRct). This enables advanced patient stratification and optimizes long-term treatment decisions for atherosclerosis, addressing a critical aspect of cardiovascular disease management. ClearRead CT excels in improving diagnostic accuracy and efficiency for nodule detection and CAC scoring, but ElucidVivo's depth in characterizing plaque vulnerability offers a higher level of impact on patient management.

Pricing & Value

Tie

Both tools maintain opaque pricing models, requiring direct contact with the vendor for details. Without any public information on pricing structures, licensing models, or demonstrable cost savings beyond general efficiency improvements, it is impossible to conduct a head-to-head comparison on this dimension.

Enterprise Readiness

ClearRead CT

ClearRead CT explicitly details flexible deployment options (on-premise and cloud) and emphasizes seamless, vendor-neutral PACS integration, which is crucial for large healthcare systems. Its proven deployment in major institutions like Duke University Medical Center and the VA, along with ISO27001 certification, demonstrates a higher level of enterprise readiness and robust integration capabilities. While ElucidVivo A.3 also integrates with PACS/EMR, its deployment details are less explicit, and it lacks the same level of documented enterprise-wide adoption and certifications.

Innovation

ElucidVivo A.3

ElucidVivo A.3 demonstrates greater innovation by uniquely quantifying specific plaque components like Lipid-Rich Necrotic Core (LRNC) and deriving fractional flow reserve (FFRct) based on vessel wall vasodilative capacity, validated against ground-truth histology. This pioneering approach provides deeper, histologically validated insights into plaque stability and hemodynamic impact, pushing the boundaries of non-invasive cardiovascular assessment. While ClearRead CT's patented vessel suppression is innovative for image clarity, ElucidVivo's comprehensive and validated plaque characterization represents a more profound advancement in diagnostic capability.

Support & Docs

ClearRead CT

ClearRead CT explicitly offers a dedicated support section on its website, including FAQs, system requirements, manuals, and 'Customer Success Live' webinars for ongoing training and support. This demonstrates a proactive approach to providing resources and assistance to users. ElucidVivo A.3's information on support and documentation is not detailed in the provided facts or search results, making it difficult to assess its offerings in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	ElucidVivo A.3	ClearRead CT
Name	ElucidVivo A.3	ClearRead CT
Company	Elucid Bioimaging	RIVERAIN TECHNOLOGIES
Description	FDA-cleared AI-powered medical image analysis system that provides quantitative analysis of arterial plaque composition and stability from CT angiography. It assists physicians in atherosclerosis patient stratification and optimizes treatment decisions by offering detailed visualization and measurement of plaque characteristics validated against histology.	FDA-cleared AI suite by Riverain Technologies for cardiothoracic health, enhancing pulmonary nodule detection and coronary artery calcification analysis in CT scans. It improves diagnostic accuracy, reduces reading times, and streamlines radiology workflows through advanced AI and vessel suppression technology.
Key Features	AI-powered quantitative analysis of arterial plaque; Objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images; Visualizes lesion-level plaque composition; Provides 3D visualization of highlighted vessels; Offers rotatable curved MPR vessel views and cross-sections; Aids in stratifying patients with atherosclerosis; Derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity; Validated on ground-truth histology.	Pulmonary Nodule Detection (solid, part-solid, ground glass); Patented Vessel Suppression (Clear Visual Intelligence); Nodule Characterization and Measurement (volume, diameter, location, type, depth); Automated Nodule Tracking and Comparison to Prior Exams; Coronary Artery Calcification (CAC) Scoring (ungated, non-contrast CTs); Reduced Reading Time (up to 36%); Improved Detection Accuracy (29% reduction in missed actionable nodules); Seamless PACS Integration / Vendor-neutral processing.
Specialties	Cardiology, Radiology, Vascular Surgery	Cardiology, Pulmonology, Radiology

Videos

Demos, reviews, and walkthroughs featuring ElucidVivo A.3 and ClearRead CT.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How deeply do these tools integrate with existing PACS and EHR systems to streamline reporting and patient management?

ElucidVivo A.3 assists physicians in atherosclerosis patient stratification and treatment decisions, implying integration with existing medical imaging and information systems, likely PACS/EMR, to facilitate detailed visualization and measurement of plaque characteristics within the clinical workflow. ClearRead CT offers seamless PACS integration and vendor-neutral processing, which helps streamline radiology workflows and reduce reading times. This integration allows for automated nodule tracking and comparison to prior exams directly within the existing imaging environment.

What specific accuracy and sensitivity metrics are available for each tool's primary diagnostic functions, and how were these validated?

ElucidVivo A.3 provides AI-powered quantitative analysis of arterial plaque composition, with its measurements of Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications validated against ground-truth histology. This validation ensures objective quantification for atherosclerosis patient stratification. ClearRead CT improves detection accuracy, demonstrating a 29% reduction in missed actionable nodules and a 21% greater nodule detection rate in studies, enhancing pulmonary nodule detection and coronary artery calcification analysis.

Beyond their listed specialties, what specific clinical scenarios or patient populations would most benefit from the unique analytical capabilities of ElucidVivo A.3 versus ClearRead CT?

ElucidVivo A.3 is particularly beneficial for stratifying patients with atherosclerosis, especially those at risk for cardiovascular events, by providing detailed insights into plaque composition and stability, including FFRct derivation. This aids in optimizing treatment decisions for vascular surgery and cardiology patients. ClearRead CT excels in scenarios requiring enhanced pulmonary nodule detection and characterization for early lung cancer screening and follow-up, as well as for comprehensive coronary artery calcification scoring from ungated CTs. It is highly valuable for pulmonology and cardiology departments seeking to improve diagnostic confidence and efficiency.

What is the expected learning curve for clinicians and how quickly can a practice expect to realize the clinical and operational benefits (time-to-value) from implementing each system?

ElucidVivo A.3 involves intricate medical imaging analysis and detailed visualizations for plaque quantification, which may suggest a moderate learning curve to fully leverage its advanced capabilities. The time-to-value would likely be realized as physicians integrate the objective plaque data into their patient stratification and management protocols. ClearRead CT is designed to reduce reading times by up to 36% and improve detection accuracy, suggesting a relatively quick time-to-value through immediate workflow efficiencies and enhanced diagnostic confidence. Its seamless PACS integration aims to minimize disruption and facilitate rapid adoption.

Are customer references or case studies available to illustrate the real-world impact and user satisfaction with each tool in clinical practice?

While specific customer references for ElucidVivo A.3 are not detailed in the provided information, its validation against histology and use in studies like EVAPORATE suggest clinical application and evaluation. For ClearRead CT, numerous case studies and real-world results are available from institutions like Regional Medical Imaging, University Hospital of Zurich, Duke University Medical Center, and Jefferson Einstein Medical Center, demonstrating its positive impact on lung cancer screening programs and workflow benefits.